US Patent

US12521390 — Dosage forms for Tyk2 inhibitors

Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2043-02-11 · 17y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable and bioavailable formulations of the Tyk2 inhibitor BMS-986165 for treating autoimmune and auto-inflammatory diseases.

USPTO Abstract

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

Drugs covered by this patent

Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3434`	—	Sotyktu

Patent Metadata

Patent number: US12521390
Jurisdiction: US
Classification: Method of Use
Expires: 2043-02-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.